中文
Introducing GeoFlow V2: Next-Generation Protein Foundation Model Unifying Structure Prediction and De Novo Design
Releasing GeoFlow V2, the world’s first unified atomic foundation model for protein design.
Category: News
PNAS Publication: BioGeometry’s AI Boosts Antibody Neutralization Against New Virus Variants by 1000-Fold
BioGeometry, in collaboration with Jianwei Zhu’s team from Shanghai Jiao Tong University’s School of Pharmacy, achieved a remarkable increase in the neutralizing activity of the 8G3 antibody against the latest JN.1 virus variant, boosting it by 1000-1500 times in a short period.
Breakthrough : BioGeometry’s AI-Driven Protein Design Revolutionizes Transmembrane Protein Solubilization and Drug Development
BioGeometry’s generative AI model, GeoFlow, redesigns the hydrophobic regions of transmembrane proteins to be soluble in water while retaining their structure and function.
Awards | BioGeometry Named “Computational Power Star” for Technological Breakthroughs at 2024 China Computational Power Conference
BioGeometry was honored with the “Computing Power Star” award for its breakthrough in denovo protein design using generative AI and geometric deep learning.
BioGeometry and GeneVax Collaborate to Enhance Vaccine Design with Advanced Protein AI Models
This strategic partnership will leverage the strengths of both companies to advance innovative vaccine development and production, creating cutting-edge vaccines in China and contributing to global health.
BioGeometry’s AI-Driven Method for Affinity Maturation Published in Nature Communications
BioGeometry and collaborators published a paper in Nature Communications, introducing the pre-trained geometric graph neural network GearBind and its application in antibody affinity maturation.
Learn MoreBioGeometry’s AI-Driven Method for Affinity Maturation Published in Nature Communications
BioGeometry and Sino Biological Deepen Strategic Cooperation to Empower Protein R&D with GenAI
Building on the success of previous projects, the two parties aim to jointly explore high-value market opportunities.
BioGeometry secures Pre-A round funding to advance GenAI for biosolutions
Driving the transformation towards a digital, intelligent and sustainable future
Learn MoreBioGeometry secures Pre-A round funding to advance GenAI for biosolutions
Introducing GeoFlow: Next-Gen Generative Model for Antibody Modeling and Design
Antibody-antigen docking performance on par with AlphaFold3
Learn MoreIntroducing GeoFlow: Next-Gen Generative Model for Antibody Modeling and Design
BioGeometry Joins Hands with Sanyou to Build a New Generation AIGC-Driven Antibody Drug Discovery Platform
Both parties will create a next-generation AIGC-driven antibody drug discovery platform jointly and promote tripartite cooperation with significant innovative drug companies or biotech firms to enhance the efficiency of new drug R&D and help pharmaceutical R&D enterprises improve their global competitiveness.